Keyphrases
T Cell Immunity
100%
T Cell Immunotherapy
100%
Gemtuzumab Ozogamicin
100%
CD33
71%
PMN-MDSC
57%
Flow Cytometry
42%
Chimeric Antigen Receptor T Cells (CAR-T)
42%
G-MDSCs
42%
T Cell Response
28%
Tumor
28%
T Cell Proliferation
28%
Cancer Subtypes
28%
University of Birmingham
14%
T Cells
14%
Alumni
14%
Cell Death
14%
Cancer Patients
14%
Electron Microscopy
14%
Therapeutic Target
14%
Confocal Microscopy
14%
T Cell Activation
14%
Immunohistochemistry
14%
Cancer Research
14%
Murine Model
14%
Children with Cancer
14%
Cell Death Pathways
14%
Transcriptomics
14%
Identifying Targets
14%
Surface Markers
14%
Immunotoxin
14%
Translational Approach
14%
Clinical Translation
14%
Multiple Cancers
14%
Tumor Cytotoxicity
14%
EGFRvIII
14%
Internalization Kinetics
14%
Treating children
14%
Anti-GD2
14%
Mesothelin
14%
Medicine and Dentistry
Immunotherapy
100%
Cancer
100%
Cellular Immunity
100%
Gemtuzumab Ozogamicin
100%
Malignant Neoplasm
57%
Neoplasm
42%
Flow Cytometry
42%
Chimeric Antigen Receptor T-Cell
42%
T-Cell Response
28%
Cell Death
28%
T Cell Proliferation
28%
Internalization
28%
T Cell
14%
Immunohistochemistry
14%
Electron Microscopy
14%
Confocal Microscopy
14%
Cytotoxicity
14%
Transcriptomics
14%
Proteus Syndrome
14%
Immunotoxin
14%
Cancer Research
14%
Cell Activity
14%
Mesothelin
14%
Hemophagocytic Lymphohistiocytosis Syndrome
14%
Immunology and Microbiology
Immunotherapy
100%
Adoptive Immunity
100%
Gemtuzumab Ozogamicin
100%
CD33
71%
Chimeric Antigen Receptor T-Cell
42%
T Cell
28%
Cell Death
28%
T Cell Proliferation
28%
Internalization
28%
Cytotoxicity
14%
Murine
14%
Electron Microscopy
14%
Myeloid
14%
Cell Activity
14%
Immunotoxin
14%
Transcriptomics
14%
Mesothelin
14%
Confocal Microscopy
14%